Zoetis Inc. $ZTS Shares Sold by Stephens Inc. AR

Stephens Inc. AR decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 129,088 shares of the company’s stock after selling 9,939 shares during the quarter. Stephens Inc. AR’s holdings in Zoetis were worth $16,242,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZTS. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Diamond Hill Capital Management Inc. purchased a new position in shares of Zoetis in the 3rd quarter worth $394,010,000. Nordea Investment Management AB raised its position in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the period. Montrusco Bolton Investments Inc. raised its position in shares of Zoetis by 256.7% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock worth $266,888,000 after buying an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after buying an additional 1,227,085 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.8%

NYSE:ZTS opened at $74.11 on Friday. The business’s 50-day moving average is $112.28 and its two-hundred day moving average is $120.94. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $172.23. The firm has a market capitalization of $31.07 billion, a PE ratio of 12.29, a price-to-earnings-growth ratio of 1.23 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Stifel Nicolaus set a $105.00 price objective on Zoetis in a research report on Friday, May 8th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Citigroup assumed coverage on Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average price target of $137.50.

Insider Activity

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 11,650 shares of company stock worth $886,384 over the last ninety days. Corporate insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.